Datapoint: BMS Faces Generic Revlimid Competition With Teva Launch

Teva Pharmaceuticals this week launched Lenalidomide, a generic alternative to Bristol Myers Squibb’s Revlimid, for the treatment of multiple myeloma. It is the first of several generic challengers to launch. For the treatment of multiple myeloma, Revlimid currently holds covered or better status for 99% of all insured lives. 17.6% of all covered lives have preferred access to Revlimid without utilization management restrictions.

SOURCE: MMIT Analytics, as of 3/8/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 26

Datapoint: J&J Sees Potential Stelara Rival in Alvotech-Teva Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 25

Datapoint: Ohio Counties Offer the Most Medicare Advantage Plans

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 24

Datapoint: Dupixent Scores First-in-Class EoE Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today